Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6015403 | Epilepsy Research | 2015 | 10 Pages |
Abstract
Hepatobiliary laboratory data and related TEAEs were not notably different between perampanel and placebo treatment groups, and no dose-related trends were observed. Based on the laboratory results from the 3 Phase III studies, perampanel (2, 4, 8, and 12Â mg) demonstrated no clinically important effects on liver function tests, indicating perampanel is an AED with a low potential for drug-induced liver toxicity.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Antonio Laurenza, Haichen Yang, Betsy Williams, Sharon Zhou, Jim Ferry,